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terventions in general practice. The addition of a disease-
specific HRQoL questionnaire in subjects who are thought
to be likely to have respiratory disease should be considered.
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A HEALTH ECONOMIC MODEL TO DESCRIBE 
THE CURRENT AND EXPECTED BURDEN
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OBJECTIVES: Chronic obstructive pulmonary disease
(COPD) is a major cause of morbidity and mortality in
Western society and its importance is increasing. The
long-term cost of COPD is currently unknown. The aim
of this study was to estimate the incidence based longi-
tudinal cost of COPD for the UK, from the payer’s per-
spective. METHODS: We examined 160 clinical and epi-
demiological papers and combined selected data in a
Markov model, with a time horizon of 20 years (40
stages of 6 months), and consisting of 29 exclusive health
states, primarily based on the evolution of forced expira-
tory volume in 1 second (FEV1), and history of hospital-
ization. Only sources that defined COPD in line with cur-
rent clinical guidelines were applied. Medical management
was obtained from database information (East of Lon-
don database) and 23 physician interviews. Health state
scores were obtained from a published cross-sectional
survey. Unit costs were obtained from official sources.
Costs are discounted at 6%. Uncertainty was estimated
through Monte Carlo analysis (1,000 runs). RESULTS:
The predicted 20 year cost for a patient starting in a mild
state (FEV1: 60–80%) or a moderate state (FEV1: 40–
59%) is £4,053 (95% CI  £3,743–£4,363) and
£11,746 (95% CI  £11,001–£12,491) respectively. The
cumulative number of Health State Adjusted Life Years is
respectively 12.10 years (95% CI  11.72–12.48) and
7.82 years (95% CI  7.51–8.13) over 20 years. CON-
CLUSIONS: Life expectancy is low, and the costs for pa-
tients starting in mild and moderate states are rather
modest, a finding that supports early diagnosis and inter-
vention. The model may serve as a framework to assess
the health economic impact of current strategies and new
treatment modalities for managing COPD.
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OBJECTIVE: The aim of this study was to compare the
cost-effectiveness of emedastine, a new topical anti-hista-
minic, with topical levocabastine in Belgium, France,
Germany, Netherlands, Norway, Portugal and Sweden,
in the treatment of allergic conjunctivitis. METHODS: A
randomized, controlled, double-masked, multi-country
clinical trial compared the efficacy and safety of emedas-
tine 0.05% bid and levocabastine 0.05% bid. Economic
comparison of a strategy with Emedastine, and a strategy
with Levocabastine, including first line therapy and fail-
ure’s therapy was modelled using clinical trial results and
standard cost approach. Societal perspective was adopted
unless no indirect costs were estimated. Only drug costs
were considered for first line treatment costs. The costs
of failure were established from a panel of Ophthalmolo-
gists and General Practitioners and focused mainly on
out-patient resource utilization: visits, drugs, lab tests,
etc. RESULTS: A total of 221 patients (109 emedastine,
112 levocabastine) presenting with allergic conjunctivitis
were followed over 42 days. From day 7 to day 42, eme-
dastine-treated patients had less itching (P  0.001) and
less redness (P  0.001). The first line treatment failure
rate was 10% less (P  0.02) in emedastine-treated pa-
tients and they had an incremental 8.5 days (P  0.01)
without symptoms. Emedastine was as safe as levocabas-
tine and well tolerated. Emedastine strategy was found
economically dominating relative to levocabastine, i.e.
less costly, and more efficacious, in Germany, Portugal
and Sweden. In France, Belgium, the Netherlands and
Norway less than one € per extra day free of symptoms
has to be paid. Sensitivity analyses were conducted which
confirmed the robustness of our findings. CONCLU-
SION: Based on results of a randomized clinical trial, and
resources and costs associated with failure having been
estimated through expert interviews, our model found
that emedastine is a cost-effective alternative in the treat-
ment of allergic conjunctivitis.
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OBJECTIVE: This literature review identifies quality of
life (QOL), symptom and patient satisfaction (PS) mea-
sures that have been used effectively with adult and pedi-
atric asthma patients in clinical trials. METHODS: A
comprehensive literature review of French or English ar-
ticles, published between 1995 and 1999, was conducted
using Medline, Excerpta Medica and Mapi Research In-
stitute databases. RESULTS: 331 abstracts were assessed
for their relevance to asthma, QOL and PS. For adult
QOL, the literature review identified six generic, ten
asthma-specific, and two respiratory disease specific mea-
sures. A comparison of domains and psychometric prop-
erties yielded 3 generic measures (SIP, NHP, SF-36) and 4
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specific measures (AQLQ-Marks; AQLQ-Juniper, LWAQ,
SGRQ) that were sufficiently comprehensive, reliable,
valid and responsive. For pediatric quality of life, the lit-
erature review identified four generic (FSII-R, KINDL,
CHQ-PF50, and How Are You questionnaire) and spe-
cific (Life Activities Questionnaire for Childhood Asthma,
Childhood Asthma Questionnaire, Pediatric Asthma Quality
of Life Questionnaire and About My Asthma) measures.
Generic measures were less sensitive in mild asthmatics.
Additional areas of interest included patient knowledge/
control of asthma, parental burden, symptom severity
and frequency. Study-specific diaries assessed symptoms
although evidence of their validity was seldom provided;
a noteworthy exception was the Asthma Symptoms
Checklist. The impact of nocturnal symptoms on sleep
was rarely measured; only the LWAQ assessed sleep,
which was found to be responsive to clinical changes. No
other asthma-specific, validated, sleep instruments exist
to date. Only five published studies on PS were found
and used study specific non-standardized measures with
no evidence of formal development/validation. CON-
CLUSION: This review suggests the need for additional
work in the assessment of responsiveness of pediatric
questionnaires, further validation of PS and the impact of
nocturnal symptoms on sleep and fatigue. Parental bur-
den and patient knowledge assessments may also aid in
determining mediating factors between disease, treatment
and outcome.
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OBJECTIVE: To evaluate the effectiveness of drug utili-
zation review (DUR) letter intervention on reducing the
cost of medications and other asthma-related expendi-
tures under Medicaid. METHODS: Between April and
July 1999, a DUR intervention designed to improve drug
use among asthmatic children, aged 5 to 18 years, en-
rolled in a mid-eastern Medicaid program was imple-
mented. The DUR intervention focused on the overuse of
short-acting 2-agonist metered dose inhalers using crite-
ria derived from NHLBI 1997 guidelines. The interven-
tion, in the form of a letter identifying the patient(s), each
patient’s prescription and medical care utilization profile,
and the DUR criteria was mailed to each of these physi-
cians. Medicaid administrative and prescription claims
data was continuously reviewed on a month-to-month
basis from July 1999 to February 2000. The intervention
group was compared to historical and concurrent com-
parison groups on several outcome variables: expenses
associated with (1) asthma-related hospitalizations, (2)
emergency department visits, and (3) asthma medication
expense. The economic impact of the intervention was
evaluated based on the analysis of differences in cost pat-
terns between the pre and the post intervention periods.
RESULTS: 382 asthmatic children with evidence of a
short-acting 2-agonist inhaler overuse and 564 physi-
cians who had treated these children were identified. A
71% decrease in short-acting 2-agonist inhaler costs was
observed in the post intervention period. A 31% and a
41% decrease in the expenses to Medicaid for leuko-
triene drugs and anti-cholinergic drugs, respectively, after
the letter intervention was recorded. There was no signif-
icant change observed in the number of recipients hospi-
talized. However there was a 24% decrease in the cost of
asthma-related hospitalizations to the State Medicaid. A
54% reduction in the respiratory related ER costs was re-
ported in the post-intervention period. CONCLUSION:
The study showed that the letter intervention was useful
in reducing asthma-related expenses to Medicaid.
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OBJECTIVE: To investigate the costs associated with
treatment of Chronic Obstructive Pulmonary Disease
(COPD) patients in a managed care population. METH-
ODS: Retrospective cohort analysis was performed using
PharMetric’s Integrated Outcomes database. Study pa-
tients were required to have a diagnosis of COPD (ICD-
9-CM  491, 492, 496). Index date was designated as
the date of first COPD diagnosis during 1997–1998.
Study patients were required to be continuously enrolled
for 6 months prior to and 12 months following the index
date. Medication use, comorbid conditions, 6-months
pre-index and 12 month post-index health care charges
were captured. RESULTS: 4,067 patients were included
in the analysis. The mean age of the sample was 59.2
years (  11.6) and 58% were female. The most com-
mon physician specialty providing the initial diagnosis
was general practitioner, accounting for 35% of all study
patients. Pulmonologists diagnosed less than 8% of pa-
tients. The most common respiratory agents were al-
buterol, ipratropium and corticosteroids, each used in
78%, 68% and 68% of COPD patients respectively. In-
creased age was associated with a significantly higher use
of ipratropium and significantly lower use of corticoster-
oids. For the 12 months following the index date, the
mean total charges for all diagnoses were approximately
$13,894 per patient (  30168), with COPD-specific
charges accounting for over 36% of the total. The single
largest cost category was inpatient care, which accounted
for 57% total (all diagnoses) charges and 76% of COPD-
specific charges. CONCLUSION: COPD is associated
with substantial medical costs, with the majority of those
costs occurring in the inpatient setting. Therefore, eco-
nomic savings could be derived from the introduction of
